Citations

Clear

3042 citation(s) found for "Kumar, S".

Elevated Dehydroepiandrosterone Sulfate Levels in 2 Patients With Prolactinomas: An Underrecognized Association
Arguinchona, Joseph , Yogi-Morren, Divya , Rad, Mona Vahidi, Doshi, Krupa , Kumar, Aditi, Vahidi Rad, Mona , Kumar, Aditi

Mayo Clinic

JCEM Case Reports | May 15, 2025 | Volume: 3 | Issue: 7 | Pages: No page available

10.1210/jcemcr/luaf111 | PMID 40384888 Get It

Abstract While adrenal androgen production is primarily regulated by ACTH, some data suggest a less common association between hyperprolactinemia and elevated dehydroepiandrosterone sulfate (DHEA-S). We describe 2 patients with this underrecognized connection. Patient 1, a 60-year-old male, was incidentally found to have bilateral adrenal masses on computed tomography during evaluation of gastrointestinal complaints. Further workup revealed elevated levels of DHEA-S and prolactin, with pituitary macroadenoma identified as the cause, given normalization of both prolactin and DHEA-S on cabergoline therapy. Patient 2, a 38-year-old male, presented with visual field defects, and subsequent pituitary magnetic resonance imaging confirmed a macroadenoma. He also had markedly elevated levels of DHEA-S and prolactin. Both patients were treated with cabergoline, leading to rapid normalization of both prolactin and DHEA-S levels. These cases demonstrate an association between hyperprolactinemia and elevated DHEA-S, supported by the normalization of levels with medical treatment of prolactinoma. Although hyperprolactinemia in the context of a prolactinoma is an uncommon cause of elevated DHEA-S, it should be considered once other etiologies have been excluded.
Extramedullary myeloma is genomically complex and characterized by near-universal MAPK pathway alterations
Zanwar, Saurabh , Howe, Michael J. A., Braggio, Esteban , Binder, Moritz , Dasari, Surendra, Kumar, Shaji , Howe, Michael, Braggio, Esteban , Binder, Moritz , Kumar, Shaji K , Novak, Joseph P. , Gonsalves, Wilson I. , Howe, Michael, Rajkumar, S. Vincent , Jevremović, Dragan

Mayo Clinic

Blood Advances | May 14, 2025 | Volume: 9 | Issue: 15 | Pages: 3979-3987

10.1182/bloodadvances.2025016619 | PMID 40367415 Get It

Abstract Extramedullary disease (EMD) is associated with an inferior prognosis and lower response rates to conventional multiple myeloma (MM)–directed therapies compared to MM without EMD. A deeper understanding of the molecular landscape and underlying drivers of EMD is essential to identify potential targets for novel therapeutic strategies. To address this, we performed whole-exome sequencing on EMD tumor tissue from 18 unique patients and bone marrow aspirates (BMAs) from 20 patients at the time of EMD development. Notably, paired EMD and BMA samples were collected from 6 patients at the point of EMD diagnosis, allowing for direct comparison of molecular profiles. Our analysis revealed a near-universal presence of mutations within the MAPK pathway in EMD samples (94%), compared to BMAs (60%; odds ratio, 10.7; P = .02; q < 0.1). Additionally, mutations in established driver genes (NRAS, KRAS, and BRAF) were common and frequently clonal, suggesting their central role in EMD pathogenesis. We also identified alterations in genes associated with cell adhesion and migration (ROBO1, ROBO2, and FAT1) and the SWI/SNF complex and epigenetic regulators (ARID1A, KMT2C, KMT2D, and EP300), although these were predominantly subclonal. Furthermore, we frequently detected biallelic alterations in the tumor suppressor genes MAX (22%), a binding partner for MYC, and CDKN2C (17%). Genomic complexity was significantly higher in EMD samples than BMAs, as evidenced by increased tumor mutational burden and the enrichment of 1q gain/amplifications. These findings underscore the distinct molecular profile of EMD compared to BMA and highlight the genomically complex and heterogeneous nature of extramedullary disease in MM.
From Data to Decisions: AI in Varicose Veins—Predicting, Diagnosing, and Guiding Effective Management
Pugalenthi, Lakshmi Sree , Garapati, Chris Alex Wesley, Maddukuri, Srivarshini , Kanwal, Fnu, Kumar, J. P. Senthil, Asadimanesh, Naghmeh, Dadwal, Surbhi, Ahluwalia, Vibhor, Senapati, Sidhartha Gautam , Arunachalam, Shivaram P. , Arunachalam, S P , Kumar, Jaspreet, Dadwal, Surbhi

Mayo Clinic

Journal of Vascular Diseases | May 14, 2025 | Volume: 4 | Issue: 2 | Pages: 19

10.3390/jvd4020019 Get It

Background: Varicose veins (VVs) of the lower limbs, characterized by palpable, dilated, and tortuous veins, affect 2–73% of the global population. Artificial intelligence (AI) offers significant potential to enhance healthcare efficiency and decision-making, particularly in managing VVs through improved risk factor identification, diagnosis, and treatment planning. Objective: This abstract explores the role of AI in VV management, focusing on its applications in risk detection, image analysis, treatment planning, and surgical interventions, while addressing challenges to its widespread adoption. Methods: AI leverages advanced techniques such as computer vision and deep learning to analyze patient data, including medical history, symptoms, physical examinations, and imaging (e.g., ultrasounds, venography). It identifies patterns in large datasets to support personalized treatment plans, early risk detection, and disease severity assessment. Results: AI demonstrates promise in automating VV detection and classification, assessing disease severity, and aiding treatment planning. It enhances surgical interventions through preoperative planning, intraoperative navigation, and recurrence risk prediction. However, its adoption is limited by a lack of large-scale studies, concerns over accuracy, and the need for regulatory and ethical oversight. Conclusion: AI has the potential to revolutionize VV management by improving diagnosis, treatment precision, and patient outcomes. Further research, validation, and integration are critical to overcoming current limitations and fully realizing AI’s capabilities in clinical practice.
Prevalence, Diagnosis, and Treatment of Cardiac Tumors: A Narrative Review
Rahouma, Mohamed , Mohsen, Hosny , Morsi, Mahmoud , Khairallah, Sherif , Azab, Lilian, Abdelhemid, Maya, Ahmed, Magdy M. El‐Sayed , El-Sayed Ahmed, Magdy M , Kumar, Akshay , Rahouma, Mohammed

Mayo Clinic

Journal of Clinical Medicine | May 13, 2025 | Volume: 14 | Issue: 10 | Pages: 3392

10.3390/jcm14103392 | PMID 40429390 Get It

Cardiac tumors, though rare, present significant diagnostic and therapeutic challenges due to their heterogeneous nature and anatomical complexity. This narrative review synthesizes current evidence on prevalence, diagnostic modalities, and management strategies for primary and metastatic cardiac tumors. Echocardiography, cardiac MRI, and CT remain cornerstone imaging tools for differentiating tumors from non-neoplastic masses, while advances in PET/CT and tissue characterization techniques refine staging and treatment planning. Surgical resection with clear margins (R0) is critical for resectable tumors, particularly benign myxomas, though malignant tumors like sarcomas require multimodal approaches combining surgery, radiotherapy, and systemic therapies. Emerging strategies such as heart autotransplantation and staged resections offer promise for complex cases, while oligometastatic disease management highlights the role of stereotactic radiotherapy and immunotherapy. Key challenges include standardizing resection margins, optimizing neoadjuvant therapies, and addressing high recurrence rates in malignancies. Future directions emphasize integrating AI-driven imaging analysis, molecular biomarkers, and genomic profiling to personalize therapies, alongside global registries to enhance data on rare tumors. Equitable access to advanced diagnostics and multidisciplinary collaboration are essential to improve outcomes. This review underscores the need for standardized guidelines, technological innovation, and patient-centered research to address gaps in cardiac oncology.
Cost per remission for mirikizumab versus ustekinumab for moderately to severely active ulcerative colitis treatment from the United States commercial payer perspective
Gulati, Ankit, Kane, Sunanda V. , Creveling, Thomas, Bires, Nicholas, Fisher, Deborah A. , Chanan, Neha, Koushik, Amit Kumar, Upadhyay, Navneet , Gulati, Ankit, Mittal, Neha

Mayo Clinic

Journal of Medical Economics | May 12, 2025 | Volume: 28 | Issue: 1 | Pages: 709-718

10.1080/13696998.2025.2503661 | PMID 40351121 Get It

The Role of Senolytics in Reducing Senescence Induced by Cannabinoids and Nicotine in Prenatal Human Lung
Alam, I. El, Belgacemi, R., Glass, I., Zana-Taeib, Elodie, Boyer, L., Danopoulos, S., Alam, D. Al, Glass, I., Zana‐Taïeb, Elodie , Boyer, L., Rehan, Virender Kumar , Prakash, Y. S. , Pabelick, Christina M. , Alam, D. Al

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7706-A7706

10.1164/ajrccm.2025.211.abstracts.a7706 Get It

Abstract Rationale: Tandem exposure to cannabinoids and nicotine during pregnancy poses significant risks to fetal development and health including low birth weight, preterm birth, and perinatal death. However, the effect of co-exposure with the most prominent cannabinoids found in Cannabis sativa (Trans-Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)) alongside nicotine on fetal lung development is not well understood. This study aims to investigate the combinatorial impact of CBD, THC, and nicotine, on human lung development through investigating cellular senescence and the potential role of senolytics in alleviating these effects.Methods: Human fetal lung explants from 10 to 16 weeks gestation were cultured on air-liquid interface and treated with various concentrations of nicotine (1µM), CBD, and THC (5µM, or 2.5µM each when used in combination), for 72 hours. To assess the effect of senolytics, the explants were also treated for 48 hours with a combination of CBD, THC, and nicotine. Subsequently, senolytics, Dasatinib (D, 250nM) and Quercetin (Q, 375nM), were added or not for an additional 24 hours. After the 72-hour treatment, explants were collected and either fixed for immunofluorescence staining (IF) analyses or used for RNA extraction and quantitative reverse transcription PCR (qRT-PCR). Additionally, the supernatants were used to evaluate the expression of the senescence-associated secretory phenotype (SASP), conducted by Eve Technologies Corporation-Canada. This study used Luminex xMAP technology for multiplexed quantification of 96 Human cytokines, chemokines, and growth factors.Results: Our results demonstrated that co-exposure to CBD, THC, and nicotine increases the expression of the senescence markers CDKN1A (0.1163±0.02384, p=0.0094, n=8) and CDKN2A (0.005793±0.002157, p=0.0516, n=8) encoding P21 and P16 respectively. Moreover, the IF staining showed increased expression of the DNA damage marker ɣH2A.X following treatment with CBD+THC+nicotine (7.375±2.154% vs 2.245±0.8329%, p=0.0604, n=6). Furthermore, the lung explants treated with cannabinoids and nicotine released cytokines and chemokines involved in immune responses and inflammation among others IL-6, IL-8, M-CSF, MCP-3, MIP-1β, TNFα, MIP-3β, and TSLP (p<0.05). The addition of D+Q reduced SASP secretion and showed a decreasing trend in expression of the senescence genes CDKN1A and CDKN2A compared to the triple treatment.Conclusion: Taken together, our results showed that the combinatorial exposure to CBD, THC, and nicotine increases senescence, DNA damage, and the senescence-associated secretory phenotypes (SASP) secretion. The use of senolytics (D+Q) may prove to be a promising therapeutic option, alleviating several of the negative effects induced by the different substances.
Incidence of Pulmonary Embolism in Patients With Acute Exacerbations of COPD Versus Non-exacerbations
LOHANA, ABHI , Versha, Fnu, Kumar, B., Neel, Sejal , Akbar, Usman Ali , Chander, Subhash

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A6158-A6158

10.1164/ajrccm.2025.211.abstracts.a6158 Get It

Abstract Introduction: Chronic Obstructive Pulmonary Disease (COPD) exacerbations increase inflammation, immobilization, and thrombotic risk, leading to a higher incidence of pulmonary embolism (PE). This study evaluates the incidence and risk of PE in patients with acute exacerbations of COPD (AECOPD) compared to those without exacerbations. Methodology: This retrospective cohort study utilized data from 94 healthcare organizations, identifying two cohorts: patients with AECOPD and those without exacerbations. Inclusion was based on ICD-10-CM codes, and individuals with malignancies, coagulation disorders, or prior PE were excluded. Propensity score matching was performed to balance the cohorts on demographics, clinical characteristics, and medications. The primary outcome was PE incidence, analyzed using risk differences, risk ratios, odds ratios, and Kaplan-Meier survival analysis to evaluate mortality outcomes associated with PE. Results: After matching, both cohorts comprised 174,345 patients each. The mean age was approximately 73 years, with a slight female predominance (49.0% in AECOPD vs. 49.3% in non-AECOPD). The incidence of PE was significantly higher in the AECOPD cohort (15%) compared to the non-AECOPD cohort (8%) (p < 0.001). Specifically, 2,162 patients (1.3%) in the AECOPD cohort developed PE, compared to 1,467 patients (0.9%) in the non-AECOPD cohort. The risk difference was 0.004 (95% CI: 0.003, 0.005; p < 0.001). The risk ratio for PE in the AECOPD cohort was 1.477 (95% CI: 1.382, 1.577), and the odds ratio was 1.483 (95% CI: 1.387, 1.585). Survival analysis revealed a probability of 95.23% in the AECOPD cohort and 97.15% in the non-AECOPD cohort, with significant differences (χ² = 153.746, df = 1, p < 0.001). The hazard ratio for mortality associated with PE was 1.517 (95% CI: 1.419, 1.621). Conclusion: Patients with AECOPD have a significantly higher incidence of pulmonary embolism compared to those without exacerbations. PE is often overlooked in AECOPD patients due to the overlap in clinical symptoms, making timely diagnosis and treatment challenging. This can result in delayed management and poor outcomes. Therefore, it is crucial to enhance understanding of the clinical manifestations, diagnosis, and treatment of COPD complicated by PE to improve diagnostic accuracy, ensure timely intervention, and optimize patient prognosis.
A Case of Refractory, Forme Fruste Non-severe Eosinophilic Granulomatosis With Polyangiitis
Karanam, V., Chetram, Deandra , Kumar, N.R.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5945-A5945

10.1164/ajrccm.2025.211.abstracts.a5945 Get It

Abstract Introduction EGPA is diagnosed clinically in patients with asthma, rhinosinusitis, and eosinophilia with end-organ involvement including neuropathy, lung infiltrates, cardiomyopathy, or kidney, gastrointestinal, or skin involvement. The five-factor score (FFS) differentiates non-severe (FFS = 0) and severe (FFS > 0) EGPA. Forme fruste, or partially treated, EGPA occurs when presumed severe eosinophilic asthma is treated with corticosteroids that can mask end organ damage typical of EGPA. We present a case of forme fruste non-severe EGPA that failed established treatments for non-severe and severe EGPA. Case Presentation This is a 38-year-old female presenting to the pulmonology clinic with three years of cough, dyspnea, wheezing, rhinorrhea, and chest heaviness. She was initially given prednisone for adult-onset asthma with improvement but was unable to taper due to symptom recrudescence on doses lower than 20 milligrams. Allergic bronchopulmonary aspergillosis testing was negative, fractional exhaled nitric oxide was elevated, pulmonary function testing showed moderate airway obstruction, and absolute eosinophil count was 11x10^3/microliter despite prednisone use. Chest computed tomography (CT) showed mild bronchial wall thickening. She was given benralizumab followed by mepolizumab, inhaled corticosteroid with a long-acting beta agonist, cetirizine, nasal budesonide, and two cycles of rituximab for possible EGPA at an outside hospital. At the current evaluation, Chest CT showed multiple nodules, patchy ground glass opacities, and bronchial wall thickening. CT sinuses showed paranasal sinus mucosal thickening with sinus outlet obstruction and nasal endoscopy showed polyps. Anti-neutrophil cytoplasmic antibody was negative, urinalysis showed mild hematuria, and bronchoalveolar lavage was negative for infection. Bone marrow did not suggest neoplasm and hematology workup did not identify other causes of hypereosinophilia. EGPA was considered highest on the differential. She was offered sinus surgery and lung biopsy for enrollment in refractory EGPA trials, but no further medical therapy was identified. Discussion This case shows the importance of recognizing potential forme fruste EGPA rather than asthma refractory to systemic glucocorticoids. Early suspicion is crucial to initiation of the proper regimen. Non-severe EGPA warrants treatment with corticosteroids and mepolizumab. Azathioprine and cyclophosphamide have demonstrated a comparable benefit in relapsing non-severe EGPA after steroid treatment, but in a single low power study. In our patient, who was refractory to glucocorticoids with mepolizumab and rituximab, there is no strong data suggesting further treatment not involving high dose steroids. In her case, chronic steroid use led to morbid obesity and obstructive sleep apnea, highlighting the importance of further research in non-severe EGPA treatment.
Short-course Versus Long-course Antibiotic Treatment for Ventilator-associated Pneumonia: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Singh, Harsimran , Fite, Amsalu, Farooqi, M., Antil, Priya, Tammineedi, Sai Niharika , Gami, NK, Komminni, Praveen Kumar , Taqi, Batoul Ali, Shaikh, Safia , Sahra, Syeda , Faran, Anna, Ahmad, Faran , Singh, H., Farooqi, M., Kakish, Diala Ra’Ed Kamal , Ahmed, Muhammad Saad , Gami, N., Shaikh, S.R.A., Cheema, Huzaifa Ahmad , Ahmad, Sharjeel , Faran, A., Torres, Antoní

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3719-A3719

10.1164/ajrccm.2025.211.abstracts.a3719 Get It

Abstract Rationale: Current guidelines recommend a short course of antibiotic therapy for ventilator-associated pneumonia (VAP) caused by non-fermenting gram-negative bacilli (NF-GNB). However, this approach has been associated with an increased risk of pneumonia recurrence. This meta-analysis aims to address inconsistencies in the literature and evaluate the efficacy of short-course versus long-course antibiotic therapy for VAP, particularly in cases due to NF- GNB. Methods: We systematically searched PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov for randomized controlled trials (RCTs) comparing short versus long courses of antibiotic therapy in patients with VAP. The primary outcomes were the risk of all-cause mortality and pneumonia recurrence. Data were analyzed using RevMan 5.4, with risk ratio (RR) and mean difference (MD) as effect measures. Results: Our pooled analysis included seven RCTs. There was no significant difference in all- cause mortality between short- and long-course antibiotic regimens (RR 1.02; 95% CI: 0.88-1.18; Figure 1). However, a short course of antibiotics increased the incidence ofpneumonia recurrence, particularly in patients with VAP due to NF-GNB (RR 1.64; 95% CI: 1.18-2.29; Figure 1). There were no significant differences between the two regimens regarding the duration of mechanical ventilation (MD 0.01 days; 95% CI: -0.51 to 0.53 days), ICU (MD 0.10 days; 95% CI: -1.00 to 1.20 days) and hospital stay (MD -0.63 days; 95% CI: -3.18 to 1.91 days), or subsequent infection with or acquisition of resistant organisms (RR 0.89; 95% CI: 0.63-1.24). Conclusions: Our meta-analysis suggests that while a short course of antibiotics increases the risk of pneumonia recurrence in NF-GNB VAP, it does not impact mortality compared to a longer course. The clinical significance of the increased recurrence of pneumonia remains uncertain, as it did not result in worse clinical outcomes. A practical approach incorporating validated clinical criteria and biomarker thresholds to guide the duration of antibiotic therapy may be more effective for patients with NF-GNB VAP. Larger RCTs are needed to drawdefinitive conclusions in this population.
Racial and Ethnic Disparities in Pulmonary Rehabilitation Utilization Among COPD Patients With Exacerbations
LOHANA, ABHI , Kumar, B Saravana, Neel, Sejal , Deepak, Vishal , Kumar, B., Chander, Subhash

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3182-A3182

10.1164/ajrccm.2025.211.abstracts.a3182 Get It

Abstract Background: Pulmonary rehabilitation (PR) is a comprehensive intervention and essential component for integrated care with patients with chronic respiratory diseases, especially Chronic Obstructive Pulmonary Disease (COPD). American Thoracic Society (ATS) strongly recommends PR for patients with COPD after exacerbation. PR has been shown to reduce mortality, improve quality of life, and decrease hospital readmissions in patients with COPD. Despite these benefits, access to PR remains unevenly distributed, particularly among racial and ethnic minorities. This study explores racial and ethnic disparities in PR utilization among COPD patients with a history of exacerbations. Methods: Utilizing data from the TrinetX Research Network, we examined two cohorts of COPD patients. Cohort 1 (N=493) consisted of patients with COPD and prior exacerbations who received PR, while Cohort 2 (N=457,573) included similar patients who did not receive PR. Demographics, specifically, race and ethnicity, were statistically analyzed to assess the presence and significance of disparities, using chi-square tests and standardized mean differences (SMD) to provide a comparative framework.Results:493 patients were in the PR group and 457,573 patients in the non-PR group, comprising 458,066 patients across both cohorts. Among the 493 patients in the PR cohort, the largest group was categorized as Other Race (192 patients, 38.9%, p < 0.001, SMD = 1.040), followed by White patients (154 patients, 31.2%, p < 0.001, SMD = 0.899). Black or African American and Asian patients were both minimally represented, with 10 patients each (2.0%, p < 0.001, SMD = 0.319 and SMD = 0.034, respectively), while 137 patients (27.8%, p < 0.001, SMD = 0.349) were of Unknown Race. In contrast, the non-PR cohort, comprising 470,239 patients, had a substantially higher proportion of White patients (330,409 patients, 72.2%) and a significantly greater representation of Black or African American individuals (42,573 patients, 9.3%, p < 0.001, SMD = 0.319) and Hispanic or Latino individuals (13,709 patients, 3.0%, p < 0.001, SMD = 0.249) compared to the PR cohort. Conclusion: This study highlights significant disparities in the utilization of PR among COPD patients, with underrepresented racial and ethnic groups demonstrating lower access to this intervention. These findings highlight the need for targeted strategies to address potential barriers to PR, promoting equitable access across diverse populations. Further investigation into structural and socioeconomic factors influencing PR access will be crucial to fostering inclusive care and reducing healthcare disparities in COPD management.